First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 2, Issue 3, 2016, Pages 169-176

  Ferrero, James ^a   Williams, Leslie ^a   Stella, Heather ^a   Leitermann, Kate ^a   Mikulskis, Alvydas ^a   O'Gorman, John ^a   Sevigny, Jeff ^a  

^a BIOGEN   (United States)

Author keywords

Adverse events; Alzheimer's disease; Clinical trial; Monoclonal antibody; Pharmacokinetics

Indexed keywords

ADUCANUMAB; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV-TR; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOGENICITY; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; PAIN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

EID: 84983458982     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2016.06.002     Document Type: Article

References (22)

1. [1] Alzheimer's Disease International. World Alzheimer Report 2009. Available at: https://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf. Accessed June 1, 2016.
2. [2] Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
3. [3] Hardy, J.A., Higgins, G.A., Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992), 184–185.
4. [4] Hampel, H., Shen, Y., Walsh, D.M., Aisen, P., Shaw, L.M., Zetterberg, H., et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 223 (2010), 334–346.
5. [5] Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., et al. Amyloid ß deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12 (2013), 357–367.
6. [6] Jack, C.R. Jr., Wiste, H.J., Lesnick, T.G., Weigand, S.D., Knopman, D.S., Vemuri, P., et al. Brain beta-amyloid load approaches a plateau. Neurology 80 (2013), 890–896.
7. [7] Koffie, R.M., Meyer-Luehmann, M., Hashimoto, T., Adams, K.W., Mielke, M.L., Garcia-Alloza, M., et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106 (2009), 4012–4017.
8. [8] Kuchibhotla, K.V., Goldman, S.T., Lattarulo, C.R., Wu, H.Y., Hyman, B.T., Bacskai, B.J., Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59 (2008), 214–225.
9. [9] Meyer-Luehmann, M., Spires-Jones, T.L., Prada, C., Garcia-Alloza, M., de, C.A., Rozkalne, A., et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451 (2008), 720–724.
10. [10] Meyer-Luehmann, M., Mielke, M., Spires-Jones, T.L., Stoothoff, W., Jones, P., Bacskai, B.J., et al. A reporter of local dendritic translocation shows plaque-related loss of neural system function in APP-transgenic mice. J Neurosci 29 (2009), 12636–12640.
11. [11] Rozkalne, A., Spires-Jones, T.L., Stern, E.A., Hyman, B.T., A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. Brain Res 1280 (2009), 178–185.
12. [12] Spires-Jones, T.L., Mielke, M.L., Rozkalne, A., Meyer-Luehmann, M., de, C.A., Bacskai, B.J., et al. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis 33 (2009), 213–220.
13. [13] Hock, C., Konietzko, U., Streffer, J.R., Tracy, J., Signorell, A., Muller-Tillmanns, B., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003), 547–554.
14. [14] Xue, D., Zhao, M., Wang, Y.J., Wang, L., Yang, Y., Wang, S.W., et al. A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Abeta42-induced cytotoxicity and increasing microglial phagocytosis. Neurobiol Dis 46 (2012), 701–709.
15. [15] Bussiere, T., Weinreb, P.H., Dunstan, R.W., Qian, F., Arast, M.F., Li, M., et al. Differential in vitro and in vivo binding profiles of BIIB037 and other anti-abeta clinical antibody candidates. Neurodegener Dis, 11(Suppl 1), 2013.
16. [16] McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
17. [17] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., 2000 Text Revision (DSM-IV-TR).
18. [18] Sevigny, J., Chiao, P., Williams, L., Chen, T., Ling, Y., O'Gorman, J., et al. Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double-blind, placebo-controlled, Phase 1b study. Alzheimers Dement, 11, 2015, P277 (abstract).
19. [19] Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., et al. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. N Engl J Med 370 (2014), 322–333.
20. [20] Ostrowitzki, S., Deptula, D., Thurfjell, L., Barkhof, F., Bohrmann, B., Brooks, D.J., et al. Mechanism of Amyloid Removal in Patients with Alzheimer Disease Treated With Gantenerumab. Arch Neurol 69 (2012), 198–207.
21. [21] Sperling, R., Salloway, S., Brooks, D.J., Tampieri, D., Barakos, J., Fox, N.C., et al. Amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease patients treated with bapineuzumab: A retrospective analysis. Lancet Neurol 11 (2012), 241–249.
22. [22] Black, R.S., Sperling, R.A., Safirstein, B., Motter, R.N., Pallay, A., Nichols, A., et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24 (2010), 198–203.